A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer

被引:49
作者
Colleoni, Marco [1 ]
Bagnardi, Vincenzo [2 ,3 ,4 ]
Rotmensz, Nicole [2 ]
Viale, Giuseppe [5 ,6 ]
Mastropasqua, Mauro [5 ,6 ]
Veronesi, Paolo [7 ]
Cardillo, Anna [1 ]
Torrisi, Rosalba [1 ]
Luini, Alberto [7 ]
Goldhirsch, Aron [8 ]
机构
[1] European Inst Oncol, Dept Med, Res Unit Med Senol, I-20141 Milan, Italy
[2] European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy
[3] Univ Milano Bicocca, Dept Stat, Milan, Italy
[4] Frontier Sci & Technol Res Fdn Inc, So Europe, Chiasso, Switzerland
[5] Univ Milan, Div Pathol, European Inst Oncol, Milan, Italy
[6] Univ Milan, Sch Med, Milan, Italy
[7] European Inst Oncol, Div Senol, Milan, Italy
[8] European Inst Oncol, Dept Med, Milan, Italy
关键词
Predictive factors; Primary therapy; Breast cancer; Predictive model; Pathological complete response; SURGICAL ADJUVANT BREAST; NEOADJUVANT CHEMOTHERAPY; COMPLETE RESPONSE; RANDOMIZED-TRIAL; NODE METASTASES; ESTROGEN; TUMOR; TRASTUZUMAB; DOXORUBICIN; THERAPIES;
D O I
10.1016/j.ejca.2010.04.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Tools able to predict pathological complete response (pCR) to preoperative chemotherapy might improve treatment outcome. Patients and methods: Data from 783 patients with invasive ductal carcinoma treated with preoperative chemotherapy and operated at the European Institute of Oncology were used to develop a nomogram using logistic regression model based on both categorical (clinical T and N, HER2/neu, grade and primary therapy) and continuous variables (age, oestrogen receptor (ER), progesterone receptor (PgR), Ki-67 expression and number of chemotherapy courses). The performance of the resulting nomogram was internally evaluated through bootstrapping methods. Finally the model was externally validated on a patient set treated in other institutions and subsequently operated at the EIO. Results: At multivariable analysis the probability of pCR was directly associated with Ki-67 expression (OR for 10% increase in the percentage of positive cells, 1.15, 95% confidence interval (CI), 1.03, 1.29) and number of chemotherapy courses (OR for one cycle increase, 1.31, 95% CI, 1.12, 1.53) and inversely associated with ER and PgR expression (ORs for 10% increase in the percentage of positive cells, 0.86, 95% CI 0.79, 0.93 and 0.82, 95% CI 0.69, 0.99, respectively). The nomogram for pCR based on these variables had good discrimination in training as well in validation set (AUC, 0.78 and 0.77). Conclusion: The use of a nomogram based on the number of preoperative courses, degree of Ki-67 and steroid hormone receptors expression may be useful for predicting the probability of pCR and for the design of the proper therapeutic algorithm in locally advanced breast cancer. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2216 / 2224
页数:9
相关论文
共 33 条
  • [1] ALBAIN K, 2004, BREAST CANC RES TREA, V88
  • [2] HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
    Andre, Fabrice
    Mazouni, Chafika
    Liedtke, Cornelia
    Kau, Shu-Wan
    Frye, Debby
    Green, Marjorie
    Gonzalez-Angulo, Ana M.
    Symmans, W. Fraser
    Hortobagyi, Gabriel N.
    Pusztai, Lajos
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (02) : 183 - 190
  • [3] Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance
    Arpino, G
    Weiss, H
    Lee, AV
    Schiff, R
    De Placido, S
    Osborne, CK
    Elledge, RM
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17): : 1254 - 1261
  • [4] The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27
    Bear, HD
    Anderson, S
    Brown, A
    Smith, R
    Mamounas, EP
    Fisher, B
    Margolese, R
    Theoret, H
    Soran, A
    Wickerham, DL
    Wolmark, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) : 4165 - 4174
  • [5] Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    Buzdar, AU
    Ibrahim, NK
    Francis, D
    Booser, DJ
    Thomas, ES
    Theriault, RL
    Pusztai, L
    Green, MC
    Arun, BK
    Giordano, SH
    Cristofanilli, M
    Frye, DK
    Smith, TL
    Hunt, KK
    Singletary, SE
    Sahin, AA
    Ewer, MS
    Buchholz, TA
    Berry, D
    Hortobagyi, GN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3676 - 3685
  • [6] Chang J, 2000, CANCER-AM CANCER SOC, V89, P2145, DOI 10.1002/1097-0142(20001201)89:11<2145::AID-CNCR1>3.3.CO
  • [7] 2-J
  • [8] Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors:: A study of preoperative treatment
    Colleoni, M
    Viale, G
    Zahrieh, D
    Pruneri, G
    Gentilini, O
    Veronesi, P
    Gelber, RD
    Curigliano, G
    Torrisi, R
    Luini, A
    Intra, M
    Galimberti, V
    Renne, G
    Nolè, F
    Peruzzotti, G
    Goldhirsch, A
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (19) : 6622 - 6628
  • [9] Cancer risk prediction models: A workshop on development, evaluation, and application
    Freedman, AN
    Seminara, D
    Gail, MH
    Hartge, P
    Colditz, GA
    Ballard-Barbash, R
    Pfeiffer, RM
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (10): : 715 - 723
  • [10] Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
    Gianni, Luca
    Eiermann, Wolfgang
    Semiglazov, Vladimir
    Manikhas, Alexey
    Lluch, Ana
    Tjulandin, Sergey
    Zambetti, Milvia
    Vazquez, Federico
    Byakhow, Mikhail
    Lichinitser, Mikhail
    Angel Climent, Miguel
    Ciruelos, Eva
    Ojeda, Belen
    Mansutti, Mauro
    Bozhok, Alla
    Baronio, Roberta
    Feyereislova, Andrea
    Barton, Claire
    Valagussa, Pinuccia
    Baselga, Jose
    [J]. LANCET, 2010, 375 (9712) : 377 - 384